The Patent Finder

Humanized Antibody Molecules Specific for IL-31

ZymoGenetics Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 8 of these applications claim priority to application 61/012,362, filed Dec 7, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,685,669Nucleic Acid Molecules Encoding Humanized Antibody Molecules Specific for IL-31
In force
 · High confidence
Merck Serono S/AIn force
High confidence
US 9,005,921Polynucleotides Encoding IL-31 Monoclonal Antibodies
In force
 · Medium confidence
Merck Serono S/AIn force
Medium confidence
US 9,416,184Method of Treating Pruritus with IL-31 Monoclonal Antibodies
In force
 · High confidence
Merck Serono S/AIn force
High confidence
US 9,738,715IL-31 Monoclonal Antibody Formulations
In force
 · High confidence
Merck Serono S/AIn force
High confidence
US 9,982,044Method of Treating Pruritus with IL-31 Monoclonal Antibody Formulations
In force
 · High confidence
Merck Serono S/AIn force
High confidence
US 11,542,327Methods of Treating Pruritic Disease with IL-31 Monoclonal Antibodies
In force
 · High confidence
Merck Serono S/AIn force
High confidence
US 10,640,559Nucleic Acid Molecules Encoding Humanized IL-31 Monoclonal Antibodies
In force
 · High confidence
Merck Serono S/AIn force
High confidence
US 8,470,979Humanized Antibody Molecules Specific for IL-31
In force
 · High confidence
ZymoGenetics, Inc.In force
High confidence
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited